A compound represented by Formula (I), or a salt or N-oxide compound thereof is provided. ##STR00001## In Formula (I), A.sup.1 to A.sup.4 each independently represents a carbon atom or nitrogen atom, X.sup.1 represents a C1-6 alkyl group or the like, n represents the number of X.sup.1 groups, R.sup.1 represents a C1-6 alkylthio group or the like, and D is a group represented by Formula (D-1) or (D-2), and ##STR00002## in Formula (D-1) and (D-2), * represents a binding position, Q represents a C1-6 alkyl group or the like, B.sup.1 and B.sup.2 each independently represents a nitrogen atom or the like, R.sup.2 represents a C1-6 alkyl group or the like that is bound to one of the nitrogen atoms in Formula (D-1), B.sup.3 and B.sup.4 each independently represents a nitrogen atom or carbon atom, R.sup.4 represents a C1-6 alkyl group or the like, and m represents the number of R.sup.4 groups.

A compound represented by Formula (I), or a salt or N-oxide compound thereof is provided. ##STR00001## In Formula (I), A.sup.1 to A.sup.4 each independently represents a carbon atom or nitrogen atom, X.sup.1 represents a C1-6 alkyl group or the like, n represents the number of X.sup.1 groups, R.sup.1 represents a C1-6 alkylthio group or the like, and D is a group represented by Formula (D-1) or (D-2), and ##STR00002## in Formula (D-1) and (D-2), * represents a binding position, Q represents a C1-6 alkyl group or the like, B.sup.1 and B.sup.2 each independently represents a nitrogen atom or the like, R.sup.2 represents a C1-6 alkyl group or the like that is bound to one of the nitrogen atoms in Formula (D-1), B.sup.3 and B.sup.4 each independently represents a nitrogen atom or carbon atom, R.sup.4 represents a C1-6 alkyl group or the like, and m represents the number of R.sup.4 groups.

Compositions used and methods are disclosed for regulation of immunity homeostasis including a combination of an Aloe extract enriched for one or more polysaccharides; a Poria extract enriched for one or more polysaccharides; and a Rosemary extract enriched for one or more polyphenolic compounds. Compositions for maintenance of immunity homeostasis by regulating HMGB1, comprising a combination of one or more polysaccharides and one or more polyphenolic compounds are disclosed. Methods for treating, managing, promoting regulation of immunity homeostasis in a mammal are disclosed that include administering an effective amount of a composition from 0.01 mg/kg to 500 mg/kg body weight of the mammal.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The oral administration of bioavailable silicic acid, such as choline-stabilized silicic acid during a period of at least 3 months daily leads to the prevention, inhibition and or treatment of periodontitis and peri-implantatis. The treatment is particularly suitable in combination with appropriate cleaning of the teeth and disinfecting the mouth, by one or more antiseptic and/or antimicrobial agent(s), as carried out at least once and suitably regularly, such as once per year, twice per year, four times per year or even every second month or every month. The treatment may be further enhanced by simultaneous administration of vitamins, trace elements, as well as by administration of a probioticum. Such additional agents may be applied separately, but are preferably incorporated in the formulation of bioavailable silicic acid.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This invention is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This invention is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.